Key Insights• According to the research report, "India EPA & DHA Market Outlook, 2031," published by Actual Market Research, the India EPA & DHA Market is expected to reach a market size of more than USD 167.58 Million by 2031. The Indian EPA & DHA market is expanding rapidly as the country faces a heavy and rising burden of cardiovascular and non-communicable disease, a large vegetarian population with structurally low intake of marine omega-3, and fast-growing consumer adoption of nutraceuticals through pharmacies and e-commerce. According to UNFPA's 2025 State of World Population report, India's population reached approximately 1.46 billion in 2025, making it the world's most populous country, with the total fertility rate falling to 1.9 births per woman and people aged 65 and older representing around 7% of the population, a share expected to rise steadily. The Registrar General of India's Report on Causes of Death 2021–2023, released in September 2025, found that non-communicable diseases accounted for 56.7% of all deaths, with cardiovascular diseases responsible for about one-third of all deaths, making them the leading cause of death in the country. A large share of Indians follow vegetarian diets and consume little or no fish, creating one of the world's largest structural gaps in dietary EPA and DHA. The growing clinical burden is placing additional pressure on India's healthcare system and consumer health sector to strengthen access to EPA and DHA through nutraceuticals, prescription medicines, infant nutrition, and fortified foods.• India's EPA & DHA market is characterized by a dynamic and rapidly evolving ecosystem comprising domestic pharmaceutical companies, nutraceutical brands, direct-to-consumer startups, e-pharmacies, quick-commerce platforms, multinational consumer health companies, and an emerging pet care industry. Leading pharmaceutical companies such as Sun Pharma, Cipla, Dr.

Reddy's, Abbott India, and Mankind Pharma market omega-3 products through physician and pharmacy channels, while consumer brands such as HealthKart (HK Vitals and MuscleBlaze), Himalaya Wellness, Wellbeing Nutrition, and Tata 1mg reach consumers online. International ingredient suppliers are expanding in India. In January 2026, Aker BioMarine appointed a country director for India and launched a distribution partnership with G.C. Chemie Pharmie to supply its Superba krill oil and Revervia algae-derived DHA to Indian manufacturers, describing India as a critical growth market. India also has domestic marine raw material supply from oil sardine and mackerel fisheries along the west coast, supporting local fish oil production.• Regulatory oversight for EPA and DHA products is administered by the Food Safety and Standards Authority of India (FSSAI) and the Central Drugs Standard Control Organisation (CDSCO). Omega-3 nutraceuticals and health supplements are regulated under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Prebiotic and Probiotic Food) Regulations, 2022, which specify permitted ingredients, usage levels, and labelling requirements, while infant formula is regulated under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.

Prescription omega-3 medicines, including icosapent ethyl and omega-3-acid ethyl esters, are approved by CDSCO under the Drugs and Cosmetics Act. FSSAI has continued to revise its nutraceutical framework, with amendments addressing ingredient lists, claims, and compliance requirements, while industry bodies such as GOED have engaged with FSSAI on the inclusion of additional omega-3 sources such as krill oil. Indian pharmaceutical companies are also significant global suppliers of generic omega-3 medicines, including generic icosapent ethyl marketed in the U.S.Market Outlook• A defining characteristic of India's EPA & DHA market is the rapid shift from physician-prescribed omega-3 toward consumer-driven nutraceutical purchases through digital channels. E-commerce marketplaces, e-pharmacies, and quick-commerce platforms such as Blinkit, Zepto, and Swiggy Instamart are making omega-3 supplements available to urban consumers within minutes, while direct-to-consumer brands promote fish oil, algal omega-3, and krill oil for heart, brain, joint, and skin health. The large vegetarian population is a key driver of demand for plant-based omega-3, and international suppliers are responding with algal DHA solutions. Aker BioMarine's introduction of Revervia algae-based DHA in India in 2026 reflects growing demand for vegetarian, high-concentration omega-3 formats suitable for Indian consumers.

Simultaneously, gym culture, sports nutrition, and preventive health awareness among younger urban professionals are expanding the consumer base beyond older adults.• The market also reflects India's growing emphasis on non-communicable disease prevention and nutrition. The National Programme for Prevention and Control of Non-Communicable Diseases promotes screening for hypertension, diabetes, and cardiovascular risk, increasing awareness of lipid management and preventive nutrition. FSSAI's Eat Right India movement promotes healthier diets and food fortification, providing a supportive backdrop for omega-3-enriched foods. In infant nutrition, India's very large birth cohort and rising urban incomes are supporting demand for DHA-fortified infant formula and maternal supplements, while the pet sector is emerging as a new demand pocket, with India's pet food market valued at approximately USD 2.4 billion in 2024 and the pet population estimated at around 42 million, according to IMARC Group.Market DynamicsDriver: Leading cardiovascular disease burden and a large structural omega-3 intake gapIndia's EPA & DHA market is primarily driven by the high and rising burden of cardiovascular disease and the country's large structural gap in dietary omega-3. Cardiovascular diseases cause about one-third of all deaths in India, and non-communicable diseases account for 56.7% of deaths, according to the Report on Causes of Death 2021–2023. Indians are at elevated risk of premature coronary artery disease, and dyslipidemia, including high triglycerides, is widespread.

A large share of the population follows vegetarian diets, while fish consumption is concentrated in coastal states, resulting in low average intake of EPA and DHA. Physicians, particularly cardiologists and diabetologists, commonly recommend omega-3 for triglyceride management, while consumers increasingly purchase omega-3 supplements for general wellness. As awareness of preventive health continues to grow, pharmacies and digital platforms are witnessing rapidly rising demand for EPA and DHA products.Challenge: Price sensitivity, product quality variability, and regulatory evolutionOne of the principal challenges facing India's EPA & DHA market is high price sensitivity among consumers, which limits the adoption of premium high-concentration fish oil, krill oil, and algal oil products outside major cities. The market also faces variability in product quality, with concerns about oxidation, actual EPA and DHA content, and adulteration in lower-priced products sold online. FSSAI's evolving nutraceutical regulations require manufacturers to adapt formulations, labels, and claims, and the approval of additional omega-3 sources such as krill oil remains under discussion. Additionally, India relies on imports for most refined, concentrated, and algal omega-3 ingredients, exposing manufacturers to exchange rate movements and global raw material prices.

Peru's first 2026 north-central anchovy quota was set approximately 36% lower than in 2025, while Indian oil sardine landings are also subject to significant year-to-year variability. Together, these factors contribute to pricing pressure and inconsistent consumer experience.Trend: Vegetarian omega-3, quick-commerce growth, and the emergence of pet nutritionIndia is experiencing a significant shift toward vegetarian omega-3 solutions and digital-first distribution. Algal DHA and EPA products are gaining traction among vegetarian consumers, while international suppliers such as Aker BioMarine are introducing high-concentration algal DHA through local distribution partners. Quick-commerce and e-pharmacy platforms are expanding access to omega-3 supplements across major cities, while direct-to-consumer brands are using social media and influencer marketing to educate younger consumers. Simultaneously, the pet sector is emerging as a fast-growing demand pocket. Godrej Consumer Products entered pet food in April 2025 with plans to invest INR 500 crore over five years, Nestlé took a minority stake in Drools Pet Food in May 2025, and Reliance Consumer Products launched its Waggies pet food brand in November 2025.

Premium pet foods and supplements increasingly incorporate fish oil for skin, coat, and joint health.Policies• FSSAI Nutraceutical Regulations, 2022: Omega-3 health supplements and nutraceuticals containing EPA and DHA are regulated under the Food Safety and Standards (Health Supplements, Nutraceuticals, Food for Special Dietary Use, Food for Special Medical Purpose, Prebiotic and Probiotic Food) Regulations, 2022, which specify permitted ingredients and sources, usage levels, labelling, and claims requirements, with FSSAI licensing required for manufacturers and importers.• Infant Nutrition Regulations, 2020: Infant formula and follow-up formula are regulated under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, which set compositional requirements, including provisions for DHA and ARA, and require BIS certification for infant food products.• CDSCO Drug Approval: Prescription omega-3 medicines, including icosapent ethyl and omega-3-acid ethyl esters, are approved by CDSCO under the Drugs and Cosmetics Act, with Indian manufacturers also producing generic omega-3 medicines for export to regulated markets such as the U.S.• Food Fortification and Eat Right India: FSSAI's food fortification standards and the Eat Right India movement promote healthier diets and the fortification of staple foods, providing a framework for omega-3-enriched foods and beverages.• Labelling, Claims, and Advertising Standards: FSSAI's labelling and display regulations and its regulations on advertising and claims govern how omega-3 products can describe their benefits, prohibiting misleading claims and requiring scientific substantiation, with enforcement extending to e-commerce food business operators.Segment AnalysisIndia EPA & DHA Market By Product Type• Docosahexaenoic Acid (DHA) maintains an important position within India, particularly in infant formula, maternal supplements, children's nutrition, and vegetarian algal DHA products. Algal DHA is especially relevant for India's large vegetarian population.• Eicosapentaenoic Acid (EPA) represents the fastest-growing product type segment in India, driven by physician recommendation of high-EPA concentrates and icosapent ethyl for triglyceride management and cardiovascular risk reduction among patients with diabetes and dyslipidemia.India EPA & DHA Market By Source• Fish Oil represents the leading revenue-generating source category in India due to its cost-effectiveness and widespread physician recommendation, supplied through a mix of domestic sardine oil and imported refined oils.• Algae Oil represents the fastest-growing source category in India, driven by vegetarian demand and the introduction of high-concentration algal DHA by international suppliers, including Aker BioMarine's Revervia in 2026.• Krill Oil is a premium source category with limited but growing presence, with Aker BioMarine launching distribution of Superba krill oil to Indian manufacturers in 2026, subject to regulatory requirements.• Other Marine Sources hold a niche position in the Indian market, including cod liver oil and shark liver oil, primarily used in traditional supplements and children's products.India EPA & DHA Market By Application• Dietary Supplements represent the largest application segment in India, distributed through pharmacies, e-commerce, e-pharmacies, and quick-commerce platforms, with omega-3 among the most widely purchased nutraceuticals.• Pharmaceuticals represent a significant application segment, including prescription omega-3 medicines for hypertriglyceridemia and cardiovascular risk reduction, as well as generic omega-3 medicines manufactured in India for export.• Infant Formula represents a strategically important application segment, with DHA included in many infant formulas and growing-up milks, supported by India's large birth cohort and rising urban incomes.• Food & Beverages encompasses omega-3-enriched milk, eggs, edible oils, and functional foods, supported by FSSAI's fortification framework.• Clinical Nutrition & Medical Foods includes enteral and parenteral nutrition products containing fish oil, used in hospitals for critically ill, surgical, and oncology patients.• Pet Nutrition represents the fastest-growing application segment in India, supported by a pet food market of approximately USD 2.4 billion in 2024 and a pet population of around 42 million that is expected to exceed 58 million by 2028.Major EPA & DHA Manufacturers Operating in India• Sun Pharma, Cipla, Dr. Reddy's, Mankind Pharma, Abbott India, HealthKart, Himalaya Wellness, Wellbeing Nutrition, Tata 1mg, Nestlé, Danone, Aker BioMarine, dsm-firmenich, and G.C. Chemie Pharmie are leading players in the Indian EPA & DHA market, offering prescription omega-3 medicines, nutraceuticals, DHA-fortified infant formula, and omega-3 ingredients. Aker BioMarine established local leadership and a distribution partnership with G.C. Chemie Pharmie in January 2026.

Their strong presence, physician engagement, digital capabilities, and established distribution networks have driven adoption across the Indian market.• The market is also supported by contract manufacturers, softgel producers, ingredient importers, and pet food companies, including Godrej, Nestlé (Drools), Mars, and Reliance, that provide formulation, encapsulation, and distribution support. With a large and rapidly growing consumer base and strong pharmaceutical manufacturing capabilities, India is one of the most promising omega-3 markets globally.India EPA & DHA Supply and Pricing Economics• EPA and DHA products in India represent value-added nutritional and pharmaceutical products whose pricing depends on source, concentration, brand positioning, and channel. Pricing varies considerably between low-cost fish oil capsules, physician-prescribed brands, krill oil, and algal oil.• Imported refined and algal oil prices are influenced by the rupee exchange rate and global raw material costs. The reduced 2026 Peruvian anchovy quota is expected to place renewed upward pressure on imported fish oil prices.• Supplements and most omega-3 medicines are paid out-of-pocket, as insurance coverage for outpatient medicines remains limited, making affordability a key purchasing factor.• E-commerce and quick-commerce platforms intensify price competition through discounts, while premium algal and krill products target higher-income urban consumers.Market Outlook by Consumer Health Spending and Supply Infrastructure• India's EPA & DHA market growth is strongly linked to rising consumer health spending, the cardiovascular disease burden, and the rapid expansion of digital and pharmacy channels, although price sensitivity, quality variability, and regulatory evolution remain significant factors influencing adoption.• Private consumer spending drives the supplement and pet nutrition segments, while physician recommendation remains central to the pharmaceutical segment. Quick-commerce and e-pharmacies are extending reach across urban India.• The future growth opportunity for EPA and DHA in India depends on expanding vegetarian algal omega-3, improving product quality standards, clarifying regulatory pathways for additional omega-3 sources, and capturing demand from the fast-growing pet sector. Greater consumer education on the omega-3 intake gap and integration of omega-3 within cardiovascular prevention programs will likely become key strategies for long-term market development.Global EPA & DHA MarketConsidered in this report• Historic Year: 2020• Base Year: 2025• Estimated Year: 2026• Forecast Year: 2031Aspects covered in this report• EPA & DHA Market with its value and forecast along with its segments• Various drivers and challenges• Ongoing trends and developments• Top profiled companies• Strategic recommendationsBy Product Type• Eicosapentaenoic Acid (EPA)• Docosahexaenoic Acid (DHA)By Application• Dietary Supplements• Infant Formula• Pharmaceuticals• Food & Beverages• Clinical Nutrition & Medical Foods• Pet NutritionBy Source• Fish Oil• Algae Oil• Krill Oil• Other Marine Sources.